Mechanisms of Acquired Resistance to First-Line Amivantamab Plus Lazertinib Vs Osimertinib: Updated Analysis from MARIPOSA

Reviews the decade-long progress in EGFR-targeted therapies and introduces the rationale for first-line dual inhibition.

Illustrates how osimertinib resistance emerges through diverse EGFR and MET alterations, leading to disease relapse.

Presents MARIPOSA trial results showing superior progression-free survival and overall survival with amivantamab plus lazertinib.

Details updated molecular analyses showing significantly fewer resistance mutations with combination therapy.

Demonstrates that longer amivantamab exposure further reduces the emergence of MET and EGFR mutations.

Reveals that resistance complexity and heterogeneity were notably lower with dual-targeted treatment.

Concludes that early EGFR-MET co-targeting can redefine first-line EGFR-mutant NSCLC management and improve survival outcomes.